A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative sepsis-induced cardiovascular, brain and kidney dysfunction - Poll - MDSpire

A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative sepsis-induced cardiovascular, brain and kidney dysfunction

  • By

  • Connie Pei Chen Ow

  • Rachel M. Peiris

  • Anton Trask-Marino

  • Sally G. Hood

  • Ashenafi H. Betrie

  • Darius J. R. Lane

  • Rinaldo Bellomo

  • Mark P. Plummer

  • Clive N. May

  • Yugeesh R. Lankadeva

  • December 28, 2025

  • 0 min

Share

Original Source(s)

A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative sepsis-induced cardiovascular, brain and kidney dysfunction

  • by Connie Pei Chen Ow, Rachel M. Peiris, Anton Trask-Marino, Sally G. Hood, Ashenafi H. Betrie, Darius J. R. Lane, Rinaldo Bellomo, Mark P. Plummer, Clive N. May, Yugeesh R. Lankadeva

  • December 28, 2025

Related Content

Compliance of procalcitonin-guided antibiotic therapy in adult infectious patients in China: a multicenter real-world retrospective study

Correlation of Shock-Lactate Index with 28-Day Mortality in Patients Experiencing Sepsis-Related AKI: An Analysis Using the MIMIC-IV Database

The mechanism of gut microbiota in septic cardiomyopathy based on the bulk transcriptome and Mendelian randomization analysis